InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.670 0.66 (6,600%)+
Announcement
Release
27 Apr 2026 8:56AM
Price at Release
$0.010
Full Release
download
Summary
Alterity Therapeutics Limited has announced receiving positive feedback from the FDA following a Type C Meeting concerning the Phase 3 development program for ATH434 in treating Multiple System Atrophy (MSA). This feedback aligns with Alterity's plans on the chemistry, manufacturing, and control (CMC) aspects of ATH434, supporting readiness for Phase 3 initiation with simultaneous manufacturing scale-up. The FDA's endorsement of the plans for manufacturing and testing ATH434 represents a significant step towards the Phase 3 trial and eventual commercialization, contingent on approval. The company is scheduled to have an End-of-Phase 2 meeting with the FDA by mid-2026.
Key Points
  • Positive FDA feedback received for ATH434's Phase 3 CMC elements.
  • Approval of plans for manufacturing and testing ATH434.
  • Readiness for Phase 3 trial initiation confirmed.
  • Manufacturing scale-up to progress alongside trial preparations.
  • End-of-Phase 2 meeting with FDA scheduled for mid-2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.